March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
March 20th 2023
Chemotherapy for Treatment of Grade II GliomasDecember 15th 2014
In this article, we provide a brief overview of the management of grade II astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas-the three most heavily encountered and studied of the low-grade gliomas.
Tailoring Chemotherapy for Low-Grade GliomasDecember 15th 2014
The recent evidence that incorporation of chemotherapeutic interventions can result in relatively long survival times for patients with low-grade glioma highlights the need to also preserve neurocognitive function and health-related quality of life in these patients.
Management of Breast Cancer Brain Metastases Is Moving Forward, but New Options Are Still NeededJuly 15th 2014
Prevention of CNS seeding early in the metastatic disease course using drugs with both intra- and extracranial activity will be crucial to improving outcomes in patients with breast cancer brain metastases.
Approaches for Optimal Drug Development and Clinical Trial Design for Breast Cancer Brain MetastasisJuly 15th 2014
Brain metastases arising from breast cancer constitute a clinically unmet need and a situation that portends a poor prognosis with few therapeutic options.
Updates on the Management of Breast Cancer Brain MetastasesJuly 15th 2014
In this overview, we will review recent developments in the management of breast cancer brain metastases and current prospective trials of systemic therapies specifically for patients with breast cancer brain metastases, with a focus on novel pathway-specific therapies.
High-Dose Chemo Before RT Results in High Survival in Pediatric Brain TumorsJune 10th 2014
High-dose chemotherapy plus conventional radiotherapy resulted in a high 3-year overall survival in children and adolescents with newly diagnosed medulloblastoma and supratentorial primitive neuroectodermal tumor.
FLT-PET Fails to Distinguish True Glioblastoma ProgressionMay 31st 2014
Positron emission tomography using F-fluorothymidine as a tracer failed to distinguish true progression of glioblastoma from pseudoprogression in a small single-center study presented at the 2014 ASCO Annual Meeting.
Leptomeningeal Enhancement in a 58-Year-Old WomanMay 15th 2014
The patient is a 58-year-old woman who was diagnosed at an outside hospital with a World Health Organization (WHO) grade III non–contrast-enhancing right frontal anaplastic astrocytoma, with spread into the genu of the corpus callosum.
Molecular Classification of Diffuse GliomasJune 15th 2013
Significant progress has been made in defining molecular signatures in diffuse gliomas. The clinically significant genetic alterations identified to date probably represent the tip of the iceberg, since new, potentially significant biomarkers are continuously described.
Tailored Therapy in Diffuse Gliomas: Using Molecular Classifiers to Optimize Clinical ManagementJune 15th 2013
We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas.
Treatment of Anaplastic Oligodendrogliomas: Should Resources Be Used to Codify the Old or to Create the New?April 15th 2013
A turning point in therapy followed the observation that patients with AO tumors with chromosome 1p and 19q codeletion had better outcomes when treated with irradiation and PCV than did non-codeleted anaplastic oligodendroglioma patients.
Oligodendrogliomas: Questions Answered, Answers QuestionedApril 15th 2013
In light of the high bar that must be met for results to be truly practice-changing, and of the long period of time before survival results are mature in an indolent disease, the primary endpoint for clinical trials in anaplastic oligodendroglial tumors needs rethinking.